Advertisement

Topics

Stereotactic Body Radiation Therapy for Low and Intermediate Risk Prostate Cancer

2018-06-18 02:03:11 | BioPortfolio

Published on BioPortfolio: 2018-06-18T02:03:11-0400

Clinical Trials [2908 Associated Clinical Trials listed on BioPortfolio]

Stereotactic Body Radiation for Prostate Oligometastases

Men with oligometastatic prostate cancer lesions will be randomized (1:2) to observation versus SBRT. The study will NOT be blinded. Within three weeks of the initial treatment planning, S...

Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer

The purpose of this study is to evaluate the incidence of urinary and gastrointestinal acute and late side effects in patients treated with stereotactic body radiotherapy (SBRT) to the pro...

MRI Guided SBRT for Localized Prostate Cancer

This study utilizes advanced imaging techniques (mpMRI prostate scan) to select and stratify patients for two different radiotherapy regimens based on the presence/absence of identifiable ...

Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer

The hypo-FLAME study is a multicenter phase II study (n=100) to investigate whether a focal SBRT boost to the MRI-defined macroscopic tumor volume is feasible and associated with acceptabl...

Prostate Boost Irradiation With Stereotactic Body RT (SBRT)

A randomized controlled open-label trial in patients with high risk prostate cancer. Eligible and consenting patients will be randomly allocated to receive stereotactic body radiotherapy (...

PubMed Articles [2075 Associated PubMed Articles listed on BioPortfolio]

Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer.

The oligometastases is considered an intermediate state of the disease between localized and wide spread metastases. Local ablative therapy to oligometastatic prostate cancer is gaining significant tr...

Analysis of competing endogenous RNA network to identify the key RNAs associated with prostate adenocarcinoma.

Prostate adenocarcinoma (PRAD) is the most common cancer in men. The aim of this study was to reveal the critical long non-coding RNA (lncRNAs), microRNA (miRNAs) and mRNAs involved in the pathogenesi...

Maternal High-Fat Diet Promotes the Development and Progression of Prostate Cancer in Transgenic Adenocarcinoma Mouse Prostate Offspring.

We aim to investigate the impact of maternal high fat diet (HFD) on the development and progression of prostate cancer (PCa) in transgenic adenocarcinoma mouse prostate (TRAMP) offspring.

Heterogenous expression of ERG oncoprotein in Malaysian men with adenocarcinoma of the prostate.

Prostate cancer is a heterogenous disease and the mechanisms that drive it to behave differently are not well understood. Tumour expression of the ERG oncogene occurs in the majority of patients with ...

68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.

Prostate-specific membrane antigen (PSMA) ligand PET/CT is an emerging modality to detect the metastatic disease, especially in intermediate- and high-risk prostate cancer (PCa). In this study, we ana...

Medical and Biotech [MESH] Definitions

Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.

A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.

Removal of all or part of the PROSTATE, often using a cystoscope and/or resectoscope passed through the URETHRA.

A family of trypsin-like SERINE ENDOPEPTIDASES that are expressed in a variety of cell types including human prostate epithelial cells. They are formed from tissue prokallikrein by action with TRYPSIN. They are highly similar to PROSTATE-SPECIFIC ANTIGEN. EC 3.4.21.35.

Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).

More From BioPortfolio on "Stereotactic Body Radiation Therapy for Low and Intermediate Risk Prostate Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial